A Research Study to Compare Two Doses of Semaglutide Taken Once Weekly in People With Type 2 Diabetes
Condition: Diabetes Mellitus, Type 2
MeSH terms: Diabetes Mellitus; Diabetes Mellitus, Type 2
Intervention: Semaglutide; Placebo (semaglutide)
Intervention description: Semaglutide injected subcutaneously (s.c., under the skin) once-weekly. Participants will keep taking their pre-study diabetes tablets throughout the study.; Semaglutide placebo injected once-weekly from week 13 to week 40.
Phase: Phase 3
Study type: Interventional
Primary purpose: Treatment
Allocation: Randomized
Intervention model: Parallel Assignment
Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)
Masking description: Sponsor staff involved in the clinical trial is masked according to company standard procedures
Enrollment: 961.0
Sex: All
Minimum age: 18 Years
Healthy volunteers: No

Summary:

      This study compares the effect of two doses of semaglutide (1.0 mg and 2.0 mg) in people with
      type 2 diabetes (T2D). People taking part in the study will take the medicine together with
      their current diabetes medicine (sulphonylurea and/or metformin). Participants will get a
      dose of either 1.0 mg or 2.0 mg semaglutide once a week - which dose is decided by chance.
      Participants will inject semaglutide under the skin once a week. The study will last for
      about 49 weeks. Participants will have 9 clinic visits and 2 phone calls with the study
      doctor. At the visits participants will have blood taken and eye tests done. Women cannot
      take part if pregnant, breast-feeding or planning to become pregnant during the study period.
      Female participants who can get pregnant will be checked 11 times for pregnancy via urine
      tests.
    

Eligibility criteria:

        Inclusion Criteria:

          -  Male or female, age equal to or above18 years at the time of signing informed consent

          -  Diagnosed with T2D at least 180 days prior to the day of screening

          -  HbA1c of 8-10% (64-86 mmol/mol) (both inclusive)

          -  Stable daily dose(s) for 90 days prior to the day of screening of:

          -  Any metformin formulations (equal to or above1500 mg or maximum tolerated or effective
             dose) alone or in combination with sulfonylureas (SU) (equal to or above half of the
             maximum approved dose according to local label or maximum tolerated or effective dose)

        Exclusion Criteria:

          -  Treatment with any medication for the indication of diabetes or obesity other than
             stated in the inclusion criteria within the past 90 days prior to the day of
             screening. However, short term insulin treatment for a maximum of 14 days prior to the
             day of screening is allowed, as is prior insulin treatment for gestational diabetes

          -  Renal impairment measured as estimated glomerular filtration rate (eGFR) value of <30
             mL/min/1.73 m^2 according to the Chronic Kidney Disease Epidemiology Collaboration
             (CKDEPI) creatinine equation as defined by KDIGO 2012 classification

          -  Uncontrolled and potentially unstable diabetic retinopathy or maculopathy. Verified by
             a fundus examination performed within the past 90 days prior to screening or in the
             period between screening and randomisation. Pharmacological pupil-dilation is a
             requirement unless using a digital fundus photography camera specified for non-dilated
             examination